Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories

Page 2

Cambricon cashes $368m in IPO
CAS-backed AI processor provider Cambricon, valued at $2.5bn in 2018, floated on Shanghai's Star Market.
AlloVir approaches public markets
Baylor College spinout AlloVir has filed to raise up to $100m in an offering that will support the clinical development of a treatment for viral diseases.
Nurix picks Nasdaq for $100m IPO filing
UC Berkeley and UC San Francisco-linked small molecule cancer drug developer Nurix Therapeutics has filed for an IPO on the Nasdaq Global Market.
Inozyme ignites IPO proceedings
Novo and Sanofi are among the investors that could exit Yale's mineralisation disease therapy developer, which has filed to raise up to $86.3m.
Immatics completes $253m reverse merger
University of Tübingen’s immuno-oncology spinout Immatics has undertaken a reverse merger with special purpose acquisition company Arya Sciences to list in the US.
QuantumCTek to compute $102m IPO
QuantumCTek has filed for a $102m initial public offering, more than a decade after being spun out of University of Science and Technology of China.
Berkeley Lights works towards $100m IPO
The UC Berkeley-linked cell biology technology provider has raised about $215m in venture funding.
Fusion Pharma fetches $213m in IPO
Facit exited McMaster University's cancer radiotherapy spinout in an upsized initial public offering after $158m in funding.
Siemens integrates UltraSoc Technologies
University of Kent's UltraSoc Technologies, which provides integrated circuit safety technologies, has agreed to an acquisition by Siemens.
Relay Therapeutics readies $200m IPO
Oncology treatment developer Relay Therapeutics is advancing research from several universities and has now filed for a $200m IPO.

test reg